tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BofA expects no changes for Regenxbio regimen after competitor safety issue

After a second death was reported for a patient using Sarepta’s (SRPT) Elevidys, BofA says the firm expects that immune prophylaxis will be in the spotlight with Sarepta planning to explore use of sirolimus in non-ambulatory patients. Immune suppression has been implemented by Regenxbio (RGNX) from the beginning, potentially contributing to superior safety for RGX-202 observed to date, adds the analyst, who expects no changes for RGX-202 after the competitor safety issue. The firm, which sees “a clear path to market” for RGX-202, maintains a Buy rating and $22 price target on Regenxbio shares.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1